TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Leukocytapheresis (LCAP) in Patients With Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed to have UC in the active stage based on clinical symptoms and findings from endoscopy~* Patients with pancolitis type or left-sided colitis type lesion of 15 cm or longer observed endoscopically~* Patients with Mayo score between 5 and 10~* Patients with Mayo sub-score (findings from flexible sigmoidoscopy) of 2 or 3~* Patients not having received any corticosteroids (referred to as steroids) (p.o., i.v., enema, suppository) within the past 6 weeks~Exclusion Criteria:~* Patients with a difficulty in peripheral vascular access~* Patients having received ACE inhibitor (at least 10 times of its half-life time for interval needed before initiating the treatment)~* Patients with toxic megacolon~* Patients with a malignant disease or its experience~* Patients with a severe cardiovascular disease (grade III or IV by the Classification of heart functions of the New York Heart Association (NYHA))~* Patients with a liver or kidney disease (AST(GOT) or ALT(GPT) or total bilirubin or creatinine level which is 2 or more times higher than the upper limit of normal (abbreviated as ULN, hereinafter)~* Patients suspected to have or having HBV or HCV or HIV or pathogenic bacteria~* Patients on anticoagulant therapy or with abnormality in the blood coagulation system (PT or PTT levels which are 1.5 or more times higher than ULN~* Pregnant women or patients with possible pregnancy~* Breast feeding women~* Patients weighing 40 kg or less~* Patients with hemoglobin level of less than 6.5 mmol/L (10.5 g/dL)~* Patients with platelet count of less than 150 x 103/mm3, 150 x 109/L (15 x 104/mm3)~* Patients with white blood cell count of less than 3.5 x 109/L (3,500/mm3)~* Patients with hypotension (with systolic blood pressure of 80 mmHg or less)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cellsorba EX (Type: EXPERIMENTAL): None
- Sham treatment (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed, unresectable locally advanced (stage IIIB with pleural effusion) and/or metastatic (stage IV) NSCLC~* Progression to first-line therapy for advanced/metastatic NSCLC~* Bi-dimensionally measurable disease (not included in radiation field)~* ECOG performance status of 0-2~* Life expectancy of more than 6 months~* Adequate liver (serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases,adequate renal function (serum creatinine \<1.5 times the upper normal limit),and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function~* Signed informed consent~Exclusion Criteria:~* Central nervous system involvement (unless if the patient has being previously irradiated and is clinically stable)~* Presence of a centrally located mass or a tumor mass in close relation to large vessels or a mass with cavitation.~* Surgery or radiation therapy within the last 14 days from study entry~* Active infection~* History of life-threatening hemoptysis / hematemesis, history of thrombosis or use of anti-coagulation therapy~* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction, ventricular arrhythmias) or stroke within the previous 6 months or uncontrolled hypertension~* Patients on other experimental treatment protocols~* History of a second primary malignancy (other than basal-cell skin carcinoma or in situ carcinoma of the cervix)~* Psychiatric illness or social situation that would preclude study compliance~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Erlotinib/Bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria~* disease duration more than 6 months and less than 3 years~* best-sitting FVC between 50% and 95% of predicted normal~* continuously treated with 100 mg riluzole daily, for at least one month~* onset of progression weakness within 36 months prior to study~* women of childbearing age be non-lactating and surgically sterile or using a highly effective method of birth control and have a negative pregnancy test~* capable of thoroughly understanding all information given and giving full informed consent according to GCP~Exclusion Criteria:~* previous participation in another clinical study within the preceding three months~* tracheotomy or assisted ventilation of any type during the preceding three months~* gastrostomy~* any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS~* presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment~* confirmed hepatic insufficiency or abnormal liver function (ASAT and/or ALAT more than 1.5 upper limit of normal)~* renal insufficiency (serum creatinine more than 2.26 mg/dl)~* evidence of major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms~* known hypersensitivity to any component of the study drugs~* likely to be not cooperative or comply with the trial requirements (as assessed by the investigator), or unable to be reached in the case of an emergency~* other antidiabetics~* heart failure or heart failure in the patients history (NYHA I to IV)~* history of macular oedema~* treatment with thiazolidinediones within 3 months prior to screening~* known or suspected history of alcohol and/or drug abuse~* treatment with gemfibrozil within 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly diagnosed with high grade glioma (grade 3 or 4) having completed surgery.~* Patients must be ≥ 18 and ≤ 70 years of age;~* WHO/ECOG Performance Status of 2 or less.~* MRI of the brain as delineated above.~* Patients must sign a study-specific informed consent prior to study entry.~Exclusion Criteria:~* Evidence of brainstem involvement on radiographs;~* Evidence of oligodendroglioma histology.~* Evidence of progressive disease at the time of study entry;~* Evidence of extracranial distant metastatic disease;~* Prior cranial irradiation;~* Patients may not be entered on other studies that have progression free, disease free, or overall survival as a primary endpoint;~* Patients with synchronous or prior malignancy, other than non-melanomatous skin cancer unless disease free greater than 3 years;~* Pregnant women are ineligible as treatment involves unforeseeable risks to the participant and to the embryo or fetus; patients with childbearing potential must practice appropriate contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Stem Cell Radiotherapy and Temozolomide (Type: EXPERIMENTAL): One treatment of 2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy over 6 weeks.~Intensity Modulated Radiation Therapy (IMRT) Is Mandated; Proton therapy (Intensity-modulated proton therapy \[IMPT\] preferred) is an acceptable treatment modality.~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent prior to inclusion into the study~* Allogeneic HSCT from HLA-identical related or unrelated donors~* Clinically confirmed acute GVHD ≥ grade II~* Age \< 70 / \> 18 years, male or female~* Karnofsky performance status \> 60 %~Exclusion Criteria:~* Oral treatment is not feasible~* Severe hepatic impairment Child-Pugh C~* Active cerebral epilepsy~* Renal failure (Creatinine clearance \< 50 ml/min)~* Life expectancy \< 3 months~* Known hypersensitivity to everolimus, sirolimus or to any of the excipients~* Confirmed pregnancy (serum β-HCG)~* Non-effective contraception for both, male and female patients, if the risk of conception exists~* Patients with limited legal capacity~* Patients unwilling and unable to undergo study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Brain Changes Throughout the ABI Wellness Program

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Enrolled in but not initiated the ABI Wellness program~2. Male or female, 19-65 years old inclusively~3. Normal hearing capabilities~4. Able to understand the informed consent form, study procedures and willing to participate in study~5. Able to keep eyes still for 6 minutes~Exclusion Criteria:~1. Clinically documented hearing issues (e.g. in-ear hearing problems, punctured ear drum, etc.)~2. Score of 7 or lower on the Mini Mental State Exam (MMSE) - Orientation subscale~3. Implanted pacemaker~4. Metal or plastic implants in skull~5. In-ear hearing aid or cochlear implant, hearing device~6. Recent (within last 6 months) acquired brain injury~7. History of other neurological disorder (e.g. brain cancer, dementia, multiple sclerosis, stroke, etc.)~8. Exposed to investigational drug or device 30 days prior to start in this study, or concurrent use of investigational drug or device while enrolled in this study~9. Not fluent in English language~10. Unable to provide informed consent~11. Previous participation in studies using the NeuroCatch Platform™~12. If female and of child-bearing potential: pregnant, suspected or planning to become pregnant or breast-feeding~13. History of seizures~14. Allergy to rubbing alcohol or EEG gel

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Full-time Cognitive Rehabilitation Program (Type: EXPERIMENTAL): Participants in full-time program will be asked to complete 4 experimental sessions with the NeuroCatch Platform™ over the course of 3 months (i.e. one session/ month).
- Part-time Cognitive Rehabilitation Program (Type: EXPERIMENTAL): Participants in the part-time program will be asked to complete 3 experimental sessions with the NeuroCatch Platform™ over 3 months (i.e. one session/1.5 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A primary histopathological and/or cytopathological diagnosis of small cell lung cancer (SCLC)~* Diagnosis of extensive stage disease (extensive stage \[ES\]-SCLC), with stage established by computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scan~* Scheduled to receive front-line platinum-based chemotherapy with carboplatin or cisplatin plus etoposide~* Ability to understand and the willingness to sign an institutional review board (IRB)-approved informed consent document~Exclusion Criteria:~* No recent chemotherapy or surgery, as defined as in the last 6 months~* Presence of a pacemaker or defibrillator~* Patients with major chronic disease known to adversely affect PA, including human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), congestive heart failure, tuberculosis~* Patients with body mass index (BMI) greater than 34 or less than 16~* Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients~* Unable or unwilling to follow protocol requirements~* Pregnant women are excluded from participation due to inability to participate in required chemotherapy regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (bioelectric impedance analysis) (Type: EXPERIMENTAL): Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has signed the trial specific informed consent form.~2. Patients ≥ 18 years old, male or female, not of childbearing potential (postmenopausal or permanently sterilized e.g., tubal occlusion, hysterectomy, bilateral salpingectomy), regardless of ethnicity.~3. Patients undergoing CABG, valve(s), CABG/valve and/or aortic root or ascending aortic aneurysm repair surgery.~4. Cleveland Clinic Renal Score ≥ 2 (higher than average risk for AKI).~5. EF ≥ 30%, evaluated within 2 months prior to screening visit.~Exclusion Criteria:~1. Cardiac surgery to be performed off pump without cardiopulmonary bypass.~2. Circulatory arrest in connection with aortic root or ascending aortic aneurysm repair surgery.~3. Confirmed or suspected endocarditis.~4. Requiring a reoperation on one of the valves within 3 months following the original valve surgical procedure.~5. Receiving Aprotinin during the trial, from Screening to Day 90.~6. Having undergone cardiovascular catheterization ≤ 48 hours prior to scheduled surgery.~7. Active peptic ulcer disease and gastritis.~8. Hemoccult positive stools, hematological, bleeding, and coagulation disorders.~9. Receiving dopamine at renal doses (2-4 mcg/kg/min), from Screening to Day 90.~10. S-Creatinine greater than 2.1 mg/dl.~11. Known or suspected hypersensitivity to the investigational medicinal product.~12. Known or suspected hypersensitivity to ondansetron or other selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonists.~13. Current participation in any other interventional clinical trial.~14. Previously dosed with AP214.~15. Use of investigational medicinal products within the previous 6 months.~16. Body weight above 140 kg.~17. History of any organ transplant.~18. Women who are of childbearing potential, pregnant or breast-feeding.~19. Current abuse of alcohol or substance, according to the investigator's medical judgment~20. Has a mental incapacity or language barriers precluding adequate understanding of trial procedures.~21. Is considered by the Investigator unsuitable to participate in the trial for any other reason for instance due to a significant serious underlying condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AP214 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men with bone-metastatic CRPC before starting the first dose of radium 223 therapy~* Laboratory requirements:~* Absolute neutrophil count (ANC) ≥ 1.5 x 109/L~* Platelet count ≥ 100 x109/L~* Hemoglobin ≥ 10.0 g/dL (100 g/L; 6.2 mmol/L)~* Total bilirubin level ≤ 1.5 institutional upper limit of normal (ULN)~* ASAT and ALAT ≤ 2.5 ULN~* • Creatinine ≤ 1.5 ULN~* Albumin \>25 g/L~* Eastern Cooperative Oncology Group Status of 0 or 1~Exclusion Criteria:~* Unable to give valid informed consent~* Contraindication for MRI as per Sunnybrook MRI questionnaire (Appendix 1).~* Claustrophobia~* Body mass index of less than 18.5 or greater than 32~* Congestive heart failure, a past or present medical history of clinically significant electrocardiogram (EKG) abnormalities, which may include QT prolongation, a family history of prolonged QT interval syndrome, or a myocardial infarction (MI) within the past 12 months with ensuing unstable EKG, or ongoing acute or chronic pulmonary bronchospastic disease, including a history of chronic obstructive pulmonary disease or asthma, with an exacerbation within the past year

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI w/ Hyperpolarized Pyruvate (13C) (Type: EXPERIMENTAL): Hyperpolarization of low natural abundance species such as 13C, when injected offers the potential of extracting metabolic information by real-time MR imaging of biochemical reactions within the body. The biochemical reactions, including lactate production, will be measured using MRI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Determinant of Blood Pressure Sensitivity to Salt Intake

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* healthy volunteers~* between 18 and 35 years odl~* BMI between 18 and 28 Kg per m2~* non smokers~* no active disease~* no alcool or drug abuse

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Diet Amiloride (Type: EXPERIMENTAL): One week Low Na diet (10 mmol/d) followed by ine week high Na diet (200 mmol/d) followed by 2 weeks administration of amiloride (10 mg the 1 st week and the 20mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues